00000000nam 2200000zi 4500
0019.953689
003CaOODSP
00520250822090351
006m     o  d f      
007cr mn|||||||||
008250729e20250325onc     o    f000 0 eng d
020 |a9780660783130
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aH14-662/2025E-PDF
0861 |aH14-662/2025-1E-PDF
24500|aEstimation of post-acute conditions associated with COVID-19 vaccine impact and effectiveness among children and adolescents in Canada : |bfindings report / |cprepared for the Public Health Agency of Canada.
264 1|aOttawa, Ontario : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cMarch 25th, 2025.
264 4|c©2025
300 |a1 online resource (88 pages) + |e1 quantitative methodological report (67 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |a"Unclassified."
500 |a"Supplier: Ipsos."
500 |a"Contract Number: CW2348463."
500 |a"Registration Number: 126-23 (HC POR 22-38).
500 |aIssued also in French under title: Estimation des syndromes post-COVID-19 associés à l'impact et à l'efficacité du vaccin contre la COVID-19 chez les enfants et les adolescents au Canada : rapport des résultats.
520 |a"Children and adolescents infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can develop long-term symptoms that are commonly known as post COVID-19 condition (PCC), Long COVID, or post-acute sequelae of SARS-CoV-2 infection (PASC). Numerous knowledge gaps remain about the frequency, characteristics, and risk factors that lead to PCC, along with PCC's impact on the everyday functioning and development of children and adolescents. There is an urgent need to improve the management of persons affected"--Background and research objectives, page 6.
650 0|aPost COVID-19 condition (Disease)|zCanada|xPublic opinion.
650 0|aCOVID-19 vaccines|zCanada|xPublic opinion.
650 0|aChronic diseases in children|zCanada|xPublic opinion.
650 0|aChronic diseases in adolescence|zCanada|xPublic opinion.
650 0|aPublic opinion|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
7102 |aIpsos (Firm), |econsultant.
77508|tEstimation des syndromes post-COVID-19 associés à l'impact et à l'efficacité du vaccin contre la COVID-19 chez les enfants et les adolescents au Canada : |w(CaOODSP)9.953690
85640|qPDF|s1.29 MB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/H14-662-2025-eng.pdf|zFindings report
85640|qPDF|s1.14 MB|uhttps://publications.gc.ca/collections/collection_2025/aspc-phac/H14-662-2025-1-eng.pdf|zQuantitative methodological report
8564 |qHTML|sN/A|uhttps://epe.bac-lac.gc.ca/100/200/301/pwgsc-tpsgc/por-ef/public_health_agency_canada/2025/126-23-e/index.html|zComplete dataset
986 |a250168